APsense

  • Our Services

    We offer best-in-class research and consulting services pertaining to the markets of all geographies. Our experienced team of business analysts and consultants has mastered fundamental and advanced market research in diverse industries.

  • Syndicated Research

    Syndicated research is the most cost-effective market research approach, which gives an analytical outlook of the competitive positioning, product positioning, and size estimation of the market at the micro level. Our off-the-shelf reports offer key market insights that industry stakeholders require to base their business strategy on. Our syndicated research services empower our clients to meet diverse market objectives.

  • Customized Research

    we also deliver customized research services to address specific needs of our clients. With a vast pool of adroit analysts who are proficient in market research, we take pride in tailoring our research services to meet our clients’ definite requirements and aid their business growth.

  • Consulting Services

    Businesses, today, need to adapt themselves to the changes that transpire in the market. Staying abreast of the market trends, therefore, becomes imperative for accomplishing business objectives.

  • Our Vision

    To be the most trusted partner in our clients' success endeavors

Showing posts with label Estrogen Receptor Positive Breast Cancer Pipeline Analysis. Show all posts
Showing posts with label Estrogen Receptor Positive Breast Cancer Pipeline Analysis. Show all posts

Estrogen Receptor-Positive (ER+) Breast Cancer Pipeline to Witness Huge R&D Investment in the Coming Years

The study analyzed that the estrogen receptor positive breast cancer pipeline comprises approximately 74 drug candidates in different stages of development.
As per the findings of the research, a major share of ER+ breast cancer pipeline drug candidates are being developed to be administered by oral route.





Chipscreen Biosciences, Ltd. is using chemo genomics approach for the development of their drug candidates in ER+ breast cancer. The approach connects small molecule structures to disease targets and therapeutic functions to accelerate the discovery process by effectively comparing the molecular profiles of successful drugs, failed drugs, and classical toxins.

The research finds that different companies have collaborated for the development of ER+ breast cancer. In January 2016, Radius Health, Inc. entered in a worldwide clinical collaboration with Novartis Pharmaceuticals to evaluate the safety and efficacy of combining investigational agent RAD1901 with LEE011 for advanced breast cancer.


Some of the key players developing drugs for Estrogen Receptor-Positive (ER+) breast cancer are Chipscreen Biosciences, Ltd., Eli Lilly & Company, Genentech, Inc., and others.

 

Contact:
Mr. Kundan Kumar
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +18887787886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Connect with us: LinkedIn | Twitter | Google + | Facebook
Share:

Popular Posts

Labels

Linkedin Profile

APSense

Business Network

Recent Posts

Research Pages